An improved ion-exchange procedure for the chromatography of the metabolites of mevalonate.

D. Skilleter,R. Kekwick

DOI: https://doi.org/10.1016/0003-2697(67)90275-8

IF: 2.9

1967-07-01

Analytical Biochemistry

Abstract:

What problem does this paper attempt to address?

Indian Consensus on the Role and Position of Angiotensin Receptor-neprilysin Inhibitors in the Management of Heart Failure

Hriday Kumar Chopra,Chandrashekhar Ponde,Gurpreet Singh Wander,Tiny Nair,Saumitra Ray,Dinesh Khullar,Navin C Nanda,Jagat Narula,Ravi R Kasliwal,Devinder Singh Rana,Ashok Kirpalani,Jitendrapal Singh Sawhney,Praveen Chandra,Yatin Mehta,Viveka Kumar,Satyendra Tiwari,Arvind K Pancholia,Vijay Kher,Sandeep Bansal,Sanjay Mittal,Praful Kerkar,Prasant Kumar Sahoo,Ramesh Hotchandani,Sunil Prakash,Nagendra Chauhan,Vishal Rastogi,Jabir Abdullakutty,S Shanmugasundaram,Mangesh Tiwaskar,Ajay Sinha,Vittul Gupta,Shishu Shankar Mishra,Satya Narayan Routray,Ashok Kumar Omar,Onkar C Swami,Aparna Jaswal,Shamsad Alam,Rajeev Passey,Rajeeve Rajput,Justin Paul,Aditya Kapoor,Prabhakar Dorairaj,Subhash Chandra,Poonam Malhotra,Vivudh Pratap Singh,Manish Bansal,Sanjay Jain,Priyank Shah,Mohan Bhargava,Ishwarappa Balekundri Vijayalakshmi,Kiron Varghaese,Dharmender Jain,Anupam Goel,Kiran Mahmood,Namrata Gaur,Rohit Tandon,Asha Moorthy,Sheeba George,V K Katyal,R R Mantri,Rahul Mehrotra,Dilip Bhalla,Vinod Mittal,Sarita Rao,Manish Jagia,Harmeet Singh,Surabhi Awasthi,Ameet Sattur,Rekha Mishra,Anand Pandey,Rajeev Chawla,Shalini Jaggi,Blessy Sehgal,Alok Sehgal,Naresh Goel,Ripen Gupta,Samir Kubba,Abhinav Chhabra,Saurabh Bagga,Rajnikant N Shastry

DOI: https://doi.org/10.59556/japi.72.0664

Abstract:The incidence of heart failure (HF) in India is estimated to be 0.5-1.7 cases per 1,000 people per year, and approximately 4,92,000-1.8 million new cases are detected every year. Despite the high rate of mortality associated with HF, most patients do not receive maximal guideline-directed medical therapy (GDMT). Current guidelines advocate early multidrug combination therapy with four classes of drugs, namely, beta-blockers (BBs), mineralocorticoid receptor antagonists (MRAs), angiotensin receptor-neprilysin inhibitors (ARNIs), and sodium-glucose transport protein 2 inhibitors (SGLT-2is), particularly in patients with heart failure with reduced ejection fraction (HFrEF). ARNIs reduce cardiac morbidity and mortality in patients with HFrEF. However, recent data indicated that only 4.8% of patients with HFrEF receive ARNI in India. Hence, at a national consensus on HF meeting, cardiology experts from India formulated a national consensus on the use of ARNI in HF based on current evidence and guidelines. The consensus states that ARNI should be used early in HF, particularly in de novo patients with HFrEF, and those with acute decompensated heart failure (ADHF), irrespective of the presence of low systolic blood pressure (SBP) or diabetes. Moreover, those with HFrEF on renin-angiotensin-aldosterone system (RAAS) inhibitors should be switched to ARNI to reduce the risk of repeated hospitalization for HF, worsening HF, and cardiac death, and to improve the quality of life (QoL). Starting ARNI during the first hospitalization is preferable, and it is safe and effective across all doses. ARNIs can also be used for secondary benefits in patients with preserved ejection fraction [heart failure with preserved ejection fraction (HFpEF)] and HF with mildly reduced EF [heart failure with mildly reduced ejection fraction (HFmrEF)].
Evidence-based Consensus On The Use Of Sacubitril Valsartan For Heart Failure Management In India

Jitendra Sawhney,Karthik Vasudevan,T. Shashikanth,Vashisth Das,K. Raghu,Naresh Goyal,Vishal Rastogi,Sameer Shrivastava,Balbir Singh,Ashwani Mehta,PV Suresh,G. Ranjit,Manoj Kumar,Priyank Jain,Anand Pandey

DOI: https://doi.org/10.1016/j.cardfail.2023.10.293

IF: 6.592

2024-01-01

Journal of Cardiac Failure

Abstract:Introduction The PARADIGM-HF trial in 2014 established sacubitril/valsartan (SV) as an effective treatment for heart failure (HF). Recent trials support expanding its use and guidelines recommend its use. A consensus statement is being formulated to validate the contemporary evidence-based datasets for SV in managing HF and exploring its pleiotropic effects Methods A group of 57 leading cardiologists (VICTORY Study group) with extensive clinical experience, cumulative 1700 man hours convened in January 2023 to discuss and rate their level of agreement on 11 questions related to heart failure care, using a 5-point Likert scale. Consensus was pre-defined as a score > 100. GraphPad 9.4.0 and ANOVA were used for statistical analysis Results The highest agreement score in the decreasing rank order (of the weighted mean score), was for that; evidence from landmark trials from ARNIs have translated benefits in the real-world setting (128), uniform agreement for the principle of fantastic four drugs in HFrEF management (127.6), based on the very heterogeneous characteristics in patients with HFpEF, there is strong need to identify markers, aside from LVEF, that could potentially predict responsiveness to the therapies (123), use of additional criteria beyond LVEF for characterization may improve prediction of patient response to sacubitril/valsartan and other therapies (122.8), NT-proBNP has prognostic value independent of HF therapy and NT-proBNP baseline levels (119.1), economical ARNI would help address therapeutic inertia and provide accelerated patient benefits (116.1), biomarkers are helpful identify subsets of patients who might benefit from sacubitril/valsartan, regardless of LVEF (110), and attention should be warranted to low dose 25 mg dose in a real practice (108.5) (Table). The long-term implications (by 2030) of usage of ARNI was postulated to be for the improvement in quality of life, followed by overall decrease in mortality, improvement in the costs of care and improvement in patient satisfaction. The adjusted mean response scores (±SD, 95% CI) for consensus were for agree (58±24, 95% CI 42 to 74) followed by strongly agree (46±35, 95% CI 23 to 70), neither agree nor disagree (11±15, 95% CI 0.72 to 21), disagree (-6.4±8.7, 95% CI -12 to -0.55) Conclusions The patient-centric outcomes of ARNI clinical trials are being effectively implemented in real-world practice, but there is a need for better prognostic biomarkers to understand the progression of heart failure in patients on ARNI. ARNI can enhance access and improve quality of life, adding life into years for HF patients in a cost-effective manner

cardiac & cardiovascular systems
Consensus Statement from India on the Renal Benefits of ARNi, SGLT-2i, and Bisoprolol in Chronic Kidney Disease

H K Chopra,Dinesh Khullar,Tiny Nair,G S Wander,C K Ponde,Saumitra Ray,Navin C Nanda,Ravi R Kasliwal,D S Rana,Ashok Kirpalani,Jps Sawhney,Praveen Chandra,Yatin Mehta,Viveka Kumar,S Tewari,A K Pancholia,Vijay Kher,Sandeep Bansal,Sanjay Mittal,Praful Kerkar,P K Sahoo,Ramesh Hotchandani,Sunil Prakash,Nagendra Chauhan,Vishal Rastogi,A Jabir,S Shanmugasundaram,Mangesh Tiwaskar,Ajay Sinha,Vittul Gupta,S S Mishra,S N Routray,A K Omar,Onkar C Swami,Aparna Jaswal,Shamsad Alam,Rajeev Passey,Rajeeve Rajput,Justin Paul,Aditya Kapoor,D Prabhakar,Subhash Chandra,Poonam Malhotra,Vivudh Pratap Singh,Manish Bansal,Priyank Shah,Sanjay Jain,Mohan Bhargava,I B Vijayalakshmi,Kiron Varghaese,Dharmender Jain,Anupam Goel,Namrata Gaur,Rohit Tandon,Asha Moorthy,Sheeba George,V K Katyal,R R Mantri,Rahul Mehrotra,Dilip Bhalla,Vinod Mittal,Sarita Rao,Manish Jagia,Harmeet Singh,Surabhi Awasthi,Ameet Sattur,Rekha Mishra,Anand Pandey,Rajeev Chawla,Shalini Jaggi,Blessy Sehgal,Alok Sehgal,Naresh Goel,Ripen Gupta,Samir Kubba,Abhinav Chhabra,Saurabh Bagga,N R Shastry

DOI: https://doi.org/10.59556/japi.72.0543

Abstract:Chronic kidney disease (CKD) is a major contributor to morbidity and mortality in India. CKD often coexists with heart failure (HF), diabetes, and hypertension. All these comorbidities are risk factors for renal impairment. HF and CKD are pathophysiologically intertwined, and the deterioration of one can worsen the prognosis of the other. There is a need for safe renal pharmacological therapies that target both CKD and HF and are also useful in hypertension and diabetes. Neurohormonal activation achieved through the activation of the sympathetic nervous system (SNS), the renin-angiotensin-aldosterone system (RAAS), and the natriuretic peptide system (NPS) is fundamental in the pathogenesis and progression of CKD and HF. Angiotensin receptor neprilysin inhibitor (ARNi), sodium-glucose cotransporter 2 inhibitors (SGLT-2i), and selective β1-blocker (B1B) bisoprolol suppress this neurohormonal activation. They also have many other cardiorenal benefits across a wide range of CKD patients with or without concomitant HF, diabetes, or hypertension. This consensus statement from India explores the place of ARNi, SGLT-2i, and bisoprolol in the management of CKD patients with or without HF and other comorbidities.
State of the art on angiotensin-neprilysin inhibitors

Anusha Sunkara,Patrick T Campbell,Hector O Ventura,Selim R Krim

DOI: https://doi.org/10.23736/S2724-5683.24.06500-1

2024-06-05

Abstract:Angiotensin receptor neprilysin inhibitor (ARNI) decreases renin-angiotensin-aldosterone system (RAAS) and sympathetic nervous systems (SNS) activity promoting vasodilation, decreasing myocardial hypertrophy and fibrosis. Beyond the SNS, RAAS and natriuretic peptide systems, ARNI results in increased circulatory and myocardial nitric oxide levels activating cGMP and protein kinase G, which reduces oxidative stress, myocyte hypertrophy, cell death and has anti-thrombotic effects. ARNIs have a class I indication by heart failure (HF) guidelines in HFrEF patients with NYHA class II to III symptoms. Beyond HFrEF, the use of ARNIs has also been expanded to other clinical settings including HF with preserved ejection fraction (EF, HFpEF), acute HF, advanced HF, hypertension, arrhythmias and chronic kidney disease. This paper reviews the clinical benefits of ARNIs in both HF and the aforementioned cardiovascular conditions. We also discuss the combined use of ARNI with SGLT2i and their potential synergistic benefits on cardiovascular outcomes.
Practical approach to vasculitis.

P. Phanuphak

1983-06-01

Asian Pacific Journal of Allergy and Immunology

Abstract:the confusion and enabling a physi lergic Disease Center (Vasculitis INTRODUCTION cian to diagnose and treat vasculitis Study Group) and later from treat Vasculitis is one of the diagnoses with confidence and efficacy. How ing patients in Thailand. frequently considered during the ever, it is not intended to be an ex Approaching a patient with vasculi examination of a patient with tensive review of vasculitis; readers tis multisystem disease 0 f uncertain who want more depth are referred nature. Its manifestations are to several recent reviews. I 6 The Table 1 lists the essential steps to protean thus making diagnosis some main view-points in this paper are be taken when encountering a pos times difficult and all encompassing. drawn from the experience gained sible case of vasculitis. These steps This paper is aimed at minimizing at the University of Colorado's Alshould be carried out sequentially
Angiotensin receptor-neprilysin inhibitor in patients with heart failure and chronic kidney disease

In-Jeong Cho,Seok-Min Kang

DOI: https://doi.org/10.23876/j.krcp.21.900

2021-12-31

Kidney Research and Clinical Practice

Abstract:Despite significant advances in the management of heart failure with reduced ejection fraction (HFrEF), there remains an enormous health problem with high morbidity and mortality over the last few decades. The neprilysin inhibitor enhances the activity of natriuretic peptides, producing vasodilation, natriuresis, and diuresis. Angiotensin receptor blockers inhibit the renin-angiotensin-aldosterone system. Sacubitril/valsartan, a first-in-class angiotensin receptor-neprilysin inhibitor (ARNI), has been shown to improve cardiovascular outcomes in HFrEF and delay the progression of chronic kidney disease (CKD) in patients with HFrEF. The PARADIGM-HF study showed a reduction in diuretic need in the ARNI group. While the use of diuretics is effective in volume control in patients with HFrEF, their use has the potential to adversely affect renal function. Therefore, ARNI therapy could benefit patients with heart failure and CKD by reducing cardiovascular morbidity and mortality and possibly retarding the progression of CKD, although more clinical evidence is required in patients with severe CKD and end-stage renal disease.

urology & nephrology
Effects of sacubitril-valsartan on heart failure patients with mid-range ejection fractions: A systematic review and meta-analysis

Jianbin Qin,Weijian Wang,Ping Wei,Ping Huang,Ruizhen Lin,Jinming Yue

DOI: https://doi.org/10.3389/fphar.2022.982372

IF: 5.6

2022-10-24

Frontiers in Pharmacology

Abstract:Aim: The effect of sacubitril-valsartan (ARNI) in heart failure (HF) patients with mid-range ejection fractions (HFmrEF) remains unclear. This study aimed to investigate the effects of ARNI in HFmrEF patients. Methods: From inception to 15 February 2022, articles were searched via PubMed, Embase, Cochrane Library, Web of Science, China National Knowledge Infrastructure, Whip, and Wanfang databases. Left ventricular functions, indicators related to HF, quality of life score, 6-Minute Walk Test, total effective rate, mortality, readmission rate, and adverse events were the outcomes. Relative risk (RR), weighted mean difference (WMD), and 95% confidence interval (CI) were used to evaluate the outcomes. The heterogeneity test was conducted for each indicator and measured by I 2 statistics. Subgroup analysis was performed regarding the type of study and duration of treatment. Results: Sixteen studies involving 1,937 patients were included in this study. Our results showed ARNI was likely to improve left ventricular function by increasing the left ventricular ejection fraction (LVEF) (WMD: 2.36, 95%CI: 1.09–3.62), stroke volume (WMD: 16.800, 95%CI: 11.385–22.215), and left ventricular short-axis shortening rate (WMD: 2.05, 95%CI: 0.25–3.86), decreasing left ventricular end-diastolic dimension (WMD: −2.48, 95%CI: −3.83 to −1.13), left atrial diameter (WMD: −2.23, 95%CI: −2.83 to −1.63), C-reactive protein level (WMD: −1.40, 95%CI: −2.62 to −0.18), and N-terminal-pro B-type natriuretic peptide level (WMD: −494.92, 95%CI: −641.34 to −348.50). ARNI has a higher total effective rate (RR: 1.15, 95%CI: 1.08–1.21), Kansas City cardiomyopathy questionnaire (WMD: 4.13, 95%CI: 3.46–4.81), and 6-Minute Walk Test (WMD: 51.35, 95%CI: 26.99–75.71) compared with angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB). In addition, ARNI decreased the readmission rate (RR: 0.54, 95%CI: 0.43–0.68) (all p < 0.05). Nevertheless, there were no significant differences in the adverse outcomes. Conclusion: This meta-analysis suggests ARNI may be an effective strategy with which to improve the left ventricular function, and quality of life, and reduce the readmission rate in HFmrEF patients. However, long-term clinical studies with large samples are still needed to further explore the efficacy and safety of ARNI compared with ACEI or ARB in the HFmrEF population.

pharmacology & pharmacy
Impact of angiotensin receptor-neprilysin inhibition (ARNI) in improving ejection fraction and left and right ventricular remodeling in heart failure

Sandeep Bhushan,Xin Huang,Fenglin Jiang,Zongwei Xiao

DOI: https://doi.org/10.1016/j.cpcardiol.2024.102464

Abstract:Angiotensin receptor neprilysin inhibitors (ARNI), a new therapeutic class of agents acting on the renin angiotensin aldosterone system (RAAS) and neutral endopeptidase system has been developed in treatment of ventricular remodeling and has attracted considerable attention. The first in class is LCZ696, which is a molecule that combines Valsartan (ARB) and Sacubitril (neprilysin inhibitor) within a single substance. Sacubitril-Valsartan is the first angiotensin receptor enkephalin inhibitors (ARNI), which can block angiotensin II type 1 receptor (AT1R) while inhibiting enkephalin (NEP) and effectively reverse ventricular remodeling in heart failure patients. It has been recommended by the European and American authoritative guidelines on heart failure as Class I for the treatment of chronic heart failure particularly as intensive care medicine. Sacubitril-Valsartan demonstrated significant effects in improving left ventricular performance and remodeling in patients with heart failure with reduced ejection fraction. Sacubitril acts on increased levels of circulating natriuretic peptides by preventing their enzymatic breakdown and Valsartan, which acts to lessen the effects of the RAAS. However, not more research has been done on its effects on the right ventricle remodeling. This review aimed to assess the impact of angiotensin receptor neprilysin inhibitors on left and right ventricular remodeling in heart failure patients.
Angiotensin Receptor–Neprilysin Inhibitor in Heart Failure Patients With Renal Dysfunction

Xiaogang Zhu,Xialing Li,Lingxuan Zhu,Zichuan Tong,Xiuying Xu

DOI: https://doi.org/10.1155/2024/6231184

2024-11-06

Cardiovascular Therapeutics

Abstract:Heart failure (HF) and renal dysfunction often coexist and interact in many complex and bidirectional pathways, leading to detrimental effects on patient outcomes. The treatment of HF patients with renal dysfunction presents a significant clinical challenge. Interestingly, sacubitril/valsartan, an angiotensin receptor–neprilysin inhibitor (ARNI), may have beneficial effects on cardiac and renal outcomes in patients with HF with reduced ejection fraction, particularly by slowing the rate of decrease in the estimated glomerular filtration rate compared to a single angiotensin–converting enzyme inhibitor. Recently, more reports have emphasized the renal protection of sacubitril/valsartan in patients with HF. In HF patients with renal dysfunction, however, there is no strong evidence supporting the use of sacubitril/valsartan to reduce the absolute risk of hyperkalemia and worsening renal function; therefore, the administration of ARNI requires a careful balance between the benefits and risks. Furthermore, the lack of evidence‐based management highlights the importance of an individualized approach based on published experience and multidisciplinary collaborations, as well as underlines the need for in‐depth studies investigating the underlying mechanisms in cardiorenal interactions with a focus on treatments.

pharmacology & pharmacy,cardiac & cardiovascular systems
Efficacy of Sacubitril-Valsartan on Survival and Cardiac Remodeling in Hypotensive Heart Failure With Reduced Ejection Fraction: A Multicenter Study

Chien-Yi Hsu,Fa-Po Chung,Chieh-Ju Chao,Ying-Ju Chen,Cho-Kai Wu,Yen-Wen Wu,Jin-Long Huang,Pao-Hsien Chu,Charles Jia-Yin Hou,Hung-Yu Chang,Chung-Lieh Hung

DOI: https://doi.org/10.1016/j.mayocp.2023.07.023

IF: 11.104

2024-03-01

Mayo Clinic Proceedings

Abstract:OBJECTIVE: To investigate whether hypotensive patients diagnosed with heart failure and reduced ejection fraction (HFrEF) might benefit from angiotensin receptor-neprilysin inhibitors (ARNis) in real-world practice because patients with baseline systolic blood pressure (SBP) of less than 100 mm Hg have been excluded from landmark trials.PATIENTS AND METHODS: In this multicenter study conducted between January 1, 2013, and December 31, 2021, a total of 7562 symptomatic patients with HFrEF were enrolled and grouped by SBP (hypotension was defined as an SBP of less than 100 mm Hg) and ARNi use as follows: group 1, hypotensive/non-ARNi users (n=484); group 2, hypotensive/ARNi users (n=308); group 3, nonhypotensive/non-ARNi users (n=4560); and group 4, nonhypotensive/ARNi users (n=2210). Inverse probability of treatment weighting was used to balance baseline characteristics for survival analysis.RESULTS: Diverse baseline characteristics and lower rates of medication use were found among non-ARNi users compared with ARNi users. Hypotensive/ARNi users had lower ARNi initiation doses than nonhypotensive/ARNi users. We observed significantly lower mortality, composite heart failure hospitalization, and CV death for hypotensive/ARNi and the other 2 nonhypotensive groups (groups 3 and 4) during a median follow-up of 3.43 years (all P<.05), with a similar effect on reverse remodeling for the hypotensive/ARNi group compared with the hypotensive/non-ARNi group. The event-free survival benefits of ARNi vs renin-angiotensin system inhibitors were consistent with the lower boundary of SBP for clinical benefits found until 88 mm Hg (spline curves) after inverse probability of treatment weighting.CONCLUSION: Patients with HFrEF and hypotension may still benefit from ARNi treatment. Patients with hypotensive HFrEF should not be routinely excluded from ARNi use in a real-world setting.

medicine, general & internal
The Difference between Sacubitril Valsartan and Valsartan on Vascular Endothelial Function, APN, MMP-9, and BNP Levels in Patients with Hypertension and Chronic Heart Failure

Haiping Du,Xiao Li,Weifang Zhao,Ning Jiang

DOI: https://doi.org/10.1155/2022/9494981

2022-02-18

Abstract:Background: Sacubitril valsartan and valsartan are the first new drugs approved for angiotensin receptor neprilysin lysine inhibitors (ARNIs) in outpatients with chronic heart failure (CHF) and hypertension. Compared with enalapril, sacubitril valsartan and valsartan have been shown to reduce the mortality and morbidity of cardiovascular diseases. However, there is little actual evidence regarding the efficacy of ARNIs in hypertensive patients with CHF. Methods: From January 2019 to January 2021, 60 patients with hypertension and chronic heart failure were diagnosed and treated in our hospital. The patients were randomly divided into an observation group and a control group, with 30 cases in each group. The control group was given valsartan, the observation group was given sacubitril valsartan, and both groups were treated for six months. The endothelium-dependent vasodilation (EDD) function of the brachial artery and serum nitric oxide (NO), endothelin-1 (ET-1), carotid artery intima-media thickness, and glomerular filtration, excess rate (eGFR), and left ventricular ejection fraction (LVEF) were compared between the two groups of patients before and after treatment. The serum adiponectin (APN), matrix metalloproteinase-9 (MMP-9), and brain natriuretic peptide (BNP) levels were compared before and after treatment. Results: The total effective rate of treatment in the research group was higher than that in the control group (P < 0.05). After treatment, the cardiac function indexes LVESD and LVEDD of the two groups of patients were lower than before treatment, and LVEF was higher than before treatment, and the improvement rate of the treatment group was better than that of the control group (P < 0.05). After treatment, the serum APN of the two groups was higher than before treatment, the levels of MMP-9 and BNP were lower than before treatment, and the improvement rate of patients in the treatment group was better than that of patients in the control group (P < 0.05). There was no statistically significant in the levels of EDD, NO, and ET-1 of the two groups of patients before treatment (P < 0.05). After treatment, compared with the control group, the EDD function and NO level of the research group were significantly increased (P < 0.05), and the level of ET-1 was significantly reduced (P < 0.05). There was no statistically significant difference in carotid artery intima-media thickness, glomerular filtration rate, and left ventricular ejection fraction before and after treatment in the two groups (P < 0.05). Conclusion: In the treatment of hypertension and chronic heart failure, sacubitril valsartan can improve the clinical symptoms of patients to the greatest extent and can significantly improve the levels of LVEF, LVEDD, NT-proBNP, heart function, and other indicators. Sacubitril valsartan can increase serum APN levels, reduce MMP-9 and BNP levels, and have good clinical effects. Sacubitril valsartan has a protective effect on the vascular endothelial function of patients with hypertension and CHF. However, these results need to be confirmed in studies involving more subjects and require longer follow-up times.
Real-world experience of angiotensin receptor-neprilysin inhibitors in patients with heart failure and dialysis

I-Ning Yang,Chi-Ya Huang,Chun-Ting Yang,Han-Siong Toh,Wei-Ting Chang,Li-Wei Su,Yu-Min Lin,Ming-Cheng Wang,Hsien-Yi Wang,Chia-Te Liao

DOI: https://doi.org/10.3389/fcvm.2024.1393440

2024-07-22

Abstract:Introduction: Although angiotensin receptor-neprilysin inhibitor (ARNI) has shown promise in patients with heart failure and reduced ejection fraction (HFrEF), the treatment effect in HFrEF patients with end-stage renal disease (ESRD) undergoing dialysis is uncertain. This study aimed to examine the real-world effects of ARNI vs. angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (ACEI/ARB) in this subpopulation. Methods: This multi-institutional, retrospective study identified 349 HFrEF patients with ESRD on dialysis, who initiated either ARNI or ACEI/ARB therapy. Efficacy outcomes included rates of hospitalization for heart failure (HHF) and mortality, as well as changes in echocardiographic parameters. Safety outcomes encompassed hypotension and hyperkalemia. Treatment effects were assessed using Cox proportional hazards models, with additional sensitivity analyses for robustness. Results: Out of 349 patients screened, 89 were included in the final analysis (42 in the ARNI group and 47 in the ACEI/ARB group). After 1 year of treatment, echocardiographic measures between the two groups were comparable. The primary composite rate of HHF or mortality was 20.6 events per 100 patient-years in the ARNI group and 26.1 in the ACEI/ARB group; the adjusted hazard ratio was 0.98 (95% CI: 0.28-3.43, P = 0.97). Their safety outcomes did not differ significantly. Sensitivity analyses, including repetitive sampling, propensity score matching, and extended follow-up, corroborated these findings. Conclusion: ARNI has proven effective in treating HFrEF patients; however, significant benefits were not observed in these patients with ESRD undergoing dialysis compared with ACEI/ARB in this real-world cohort. Future research employing a more extended follow-up period, larger sample size, or randomized design is warranted to investigate the treatment effects in this subpopulation.
Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction: Rationale and Design of the PARAGON-HF Trial.

Scott D Solomon,Adel R Rizkala,Jianjian Gong,Wenyan Wang,Inder S Anand,Junbo Ge,Carolyn S P Lam,Aldo P Maggioni,Felipe Martinez,Milton Packer,Marc A Pfeffer,Burkert Pieske,Margaret M Redfield,Jean L Rouleau,Dirk J Van Veldhuisen,Faiez Zannad,Michael R Zile,Akshay S Desai,Victor C Shi,Martin P Lefkowitz,John J V McMurray

DOI: https://doi.org/10.1016/j.jchf.2017.04.013

2017-01-01

Abstract:OBJECTIVES:The PARAGON-HF (Prospective Comparison of ARNI with ARB Global Outcomes in HF With Preserved Ejection Fraction) trial is designed to determine the efficacy and safety of the angiotensin receptor neprilysin inhibitor sacubitril/valsartan compared with valsartan in patients with chronic heart failure and preserved ejection fraction (HFpEF). BACKGROUND:HFpEF is highly prevalent, associated with substantial morbidity and mortality, and in need of effective therapies that improve outcomes. The angiotensin receptor neprilysin inhibitor (ARNI) sacubitril/valsartan, which has been shown to benefit patients with heart failure (HF) and reduced ejection fraction, demonstrated favorable physiologic effects in a phase II HFpEF trial. METHODS:The PARAGON-HF trial is a randomized, double-blind, parallel group, active-controlled, event-driven trial comparing the long-term efficacy and safety of valsartan and sacubitril/valsartan in patients with chronic HFpEF (left ventricular ejection fraction ≥45%), New York Heart Association functional class II to IV symptoms, elevated natriuretic peptides, and evidence of structural heart disease. Before randomization, all patients entered sequential single-blind run-in periods to ensure tolerability of both drugs at half the target doses (i.e., valsartan titrated to 80 mg bid followed by sacubitril/valsartan 49/51 mg [100 mg] bid). The primary outcome is the composite of cardiovascular death and total (first and recurrent) HF hospitalizations. CONCLUSIONS:PARAGON-HF will determine whether sacubitril/valsartan is superior to angiotensin receptor blockade alone in patients with chronic symptomatic HFpEF. (Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction [PARAGON-HF]; NCT01920711).
Use and Benefit of Sacubitril/Valsartan in Elderly Patients with Heart Failure with Reduced Ejection Fraction

Luis Nieto Roca,Marcelino Cortés García,Jorge Balaguer Germán,Antonio José Bollas Becerra,José María Romero Otero,José Antonio Esteban Chapel,Carlos Rodríguez López,Ana María Pello Lázaro,Mikel Taibo Urquía,José Tuñón

DOI: https://doi.org/10.3390/jcm13164772

2024-08-14

Abstract:Background: Heart failure (HF) is a highly prevalent syndrome in elderly subjects. Currently, multiple drugs have shown clinical benefits in patients with HF and reduced ejection fraction (HFrEF). However, evidence is scarce in elderly patients (beyond 75 years old), even more so for the latest drugs, such as angiotensin receptor-neprilysin inhibitors (ARNIs). This study aims to evaluate the use and benefits of ARNIs in elderly patients with HFrEF. Methods: A prospective observational cohort study was designed. Patients with left ventricular systolic dysfunction (defined by left ventricular ejection fraction [LVEF] < 40%) and age ≥ 75 years from January 2016 to December 2020 were prospectively included. Patients with an indication for ARNIs at inclusion or throughout follow-up were selected. Clinical, electrocardiographic and echocardiographic variables were collected. Results: A total of 616 patients were included, 34.4% of them female, with a mean age of 83.3 years, mean LVEF of 28.5% and ischemic etiology in 53.9% of patients. Only 14.3% of patients were taking ARNIs. After a mean follow-up of 34 months, 50.2% of patients died, and 62.2% had a cardiac event (total mortality or hospital admission due to HF). Multivariate Cox regression analysis showed that the use of ARNIs was independently and significantly associated with lower rates of mortality [HR 0.36 (95% CI 0.21-0.61)], with similar results in relation to all-cause mortality in a propensity-score-matched analysis [HR 0.33 (95% CI 0.19-0.57)]. Conclusions: We observed an important underuse of ARNIs in a cohort of elderly HFrEF patients, in which treatment with ARNIs was associated with a significant reduction in mortality. Greater implementation of clinical practice guidelines in this group of patients could improve their prognosis.
Sacubitril/valsartan and arrhythmic burden in patients with heart failure and reduced ejection fraction: a systematic review and meta-analysis

A. Pozzi,R. Abete,E. Tavano,S. L. Kristensen,F. Rea,A. Iorio,A. Iacovoni,G. Corrado,C. Wong

DOI: https://doi.org/10.1007/s10741-023-10326-1

2023-07-01

Heart Failure Reviews

Abstract:The aim of this study was to assess whether angiotensin receptor/neprilysin inhibitor (ARNI) decreases ventricular arrhythmic burden compared to angiotensin-converting enzyme inhibitors or angiotensin receptor antagonist (ACE-I/ARB) treatment in chronic heart failure with reduced ejection fraction (HFrEF) patients. Further, we assessed if ARNI influenced the percentage of biventricular pacing. A systematic review of studies (both RCTs and observational studies) including HFrEF patients and those receiving ARNI after ACE-I/ARB treatment was conducted using Medline and Embase up to February 2023. Initial search found 617 articles. After duplicate removal and text check, 1 RCT and 3 non-RCTs with a total of 8837 patients were included in the final analysis. ARNI was associated with a significative reduction of ventricular arrhythmias both in RCT (RR 0.78 (95% CI 0.63–0.96); p = 0.02) and observational studies (RR 0.62; 95% CI 0.53–0.72; p < 0.001). Furthermore, in non-RCTs, ARNI also reduced sustained (RR 0.36 (95% CI 0.2–0.63); p < 0.001), non-sustained VT (RR 0.67 (95% CI 0.57–0.80; p = 0.007), ICD shock (RR 0.24 (95% CI 0.12–0.48; p < 0.001), and increased biventricular pacing (2.96% (95% CI 2.25–3.67), p < 0.001). In patients with chronic HFrEF, switching from ACE-I/ARB to ARNI treatment was associated with a consistent reduction of ventricular arrhythmic burden. This association could be related to a direct pharmacological effect of ARNI on cardiac remodeling.

cardiac & cardiovascular systems
Angiotensinogen and Natriuretic Peptide mRNAs in Rat Brain: Localization and Differential Regulation by Adrenal Steroids in Hypothalamus

M. C. Ryan,P. Shen,A. Gundlach

DOI: https://doi.org/10.1016/S0196-9781(96)00329-4

IF: 3.867

1997-12-31

Peptides

Abstract:
Angiotensin Receptor-Neprilysin Inhibitors in Patients With Heart Failure With Reduced Ejection Fraction and Advanced Chronic Kidney Disease: A Retrospective Multi-Institutional Study

Fu-Chih Hsiao,Chia-Pin Lin,Chun-Chen Yu,Ying-Chang Tung,Pao-Hsien Chu

DOI: https://doi.org/10.3389/fcvm.2022.794707

IF: 3.6

2022-03-08

Frontiers in Cardiovascular Medicine

Abstract:Background Data regarding using angiotensin receptor-neprilysin inhibitor (ARNI) in patients with both heart failure with reduced ejection fraction (HFrEF) and advanced chronic kidney disease (CKD) are limited. Methods and Results Between January 2016 and December 2018, patients with HFrEF and advanced CKD (estimated glomerular filtration rate [eGFR] ≤ 30 mL/min/1.73 m 2 ) were identified from a multi-institutional database in Taiwan. Patients who had never been prescribed with an ARNI, angiotensin-converting enzyme inhibitor (ACEI), or angiotensin receptor blocker (ARB) were excluded. We used inverse probability of treatment weighting (IPTW) to balance baseline covariates, and compared outcomes between ARNI and ACEI/ARB users. There were 206 patients in the ARNI group and 833 patients in the ACEI/ARB group. After IPTW adjustment, the mean ages (65.1 vs. 66.6 years), male patients (68.3 vs. 67.9%), left ventricular ejection fraction (30.5 vs.31.2%), eGFR (20.9 vs. 20.3 mL/min/1.73 m 2 ) were comparable in the ARNI and ACEI/ARB groups. Over 85% of the patients had beta-blockers prescriptions in both groups (86.2 vs. 85.5%). After IPTW adjustment, the mean follow-up durations were 7.3 months and 6.6 months in the ARNI and ACEI/ARB groups, respectively. ARNI and ACEI/ARB users had a comparable risk of the composite clinical event (all-cause mortality or heart failure hospitalization) (hazard ratio [HR], 1.31; 95% confidence interval (CI) 0.91–1.88) and progression to dialysis (HR 1.04; 95% CI 0.54–2.03). In subgroup analysis, dialysis patients who used ARNIs were associated with higher incidence of heart failure hospitalization (subdistribution HR, 1.97; 95% CI 1.36–2.85). Conclusions Compared with ACEIs or ARBs, ARNIs were associated with comparable clinical and renal outcomes in patients with HFrEF and advanced CKD (eGFR ≤ 30 mL/min/1.73 m 2 ). In short-term, HF hospitalization may occur more frequently among ARNI users, especially in patients on dialysis.

cardiac & cardiovascular systems
Safety and efficacy of angiotensin receptor neprilysin inhibitor in improving cardiac function and blood pressure in dialysis patients

Kai Zhou,Qiuyue Zhang,Wen Dong,Xin Li,Yimiao Sun,Ying Zhang

DOI: https://doi.org/10.3389/fmed.2024.1421085

2024-09-05

Abstract:Background: The efficacy of the angiotensin receptor neprilysin inhibitor (ARNI) sacubitril/valsartan (SV) in patients with chronic kidney disease (CKD) has been established. Two meta-analyses have demonstrated its significant role in enhancing ventricular remodeling. However, the effectiveness and safety of its use in patients with end-stage renal disease (ESRD) remain unclear. Methods and results: Up to October 2023, we searched the PubMed, Embase, and Web of Science databases for studies involving ESRD patients treated with ARNI. The quality of the included studies was evaluated using the Newcastle-Ottawa Scale. Effect sizes were reported as mean differences (MD) with 95% confidence intervals (CIs). We included 10 studies, encompassing 649 patients. ARNI was associated with improvements in blood pressure and left ventricular (LV) function in ESRD patients, including systolic blood pressure (SBP) (MD -12.76 mmHg; 95% CI, -18.03 to -7.5 mmHg), diastolic blood pressure (DBP) (MD -6.41 mmHg; 95% CI, -8.10 to -4.72 mmHg), and left ventricular ejection fraction (LVEF) (MD, 4.61%; 95% CI, 1.78%-7.44%). Hemoglobin levels improved, but there were no significant statistical differences in other biomarkers for dialysis. Sacubitril/valsartan was generally well tolerated in ESRD patients. Improved indices of left ventricular function were noted at 6 months and were more pronounced at 12 months. A linear relationship between LVEF and left ventricular end-diastolic volume (LVEDV) was observed, as indicated by a high correlation coefficient (r-value). Conclusion: ARNI effectively reduces blood pressure and enhances left ventricular function in dialysis patients, with early treatment associated with greater benefits. ARNI also demonstrates a favorable safety profile in this population. Further prospective studies are required to fully understand the long-term efficacy and safety of sacubitril/valsartan in dialysis patients.
Neprilysin Inhibitors in Heart Failure: The Science, Mechanism of Action, Clinical Studies, and Unanswered Questions

Biykem Bozkurt,Ajith P Nair,Arunima Misra,Claire Z Scott,Jamal H Mahar,Savitri Fedson

DOI: https://doi.org/10.1016/j.jacbts.2022.05.010

2022-09-07

Abstract:This article provides a contemporary review and a new perspective on the role of neprilysin inhibition in heart failure (HF) in the context of recent clinical trials and addresses potential mechanisms and unanswered questions in certain HF patient populations. Neprilysin is an endopeptidase that cleaves a variety of peptides such as natriuretic peptides, bradykinin, adrenomedullin, substance P, angiotensin I and II, and endothelin. It has a broad role in cardiovascular, renal, pulmonary, gastrointestinal, endocrine, and neurologic functions. The combined angiotensin receptor and neprilysin inhibitor (ARNi) has been developed with an intent to increase vasodilatory natriuretic peptides and prevent counterregulatory activation of the angiotensin system. ARNi therapy is very effective in reducing the risks of death and hospitalization for HF in patients with HF and New York Heart Association functional class II to III symptoms, but studies failed to show any benefits with ARNi when compared with angiotensin-converting enzyme inhibitors or angiotensin receptor blocker in patients with advanced HF with reduced ejection fraction or in patients following myocardial infarction with left ventricular dysfunction but without HF. These raise the questions about whether the enzymatic breakdown of natriuretic peptides may not be a very effective solution in advanced HF patients when there is downstream blunting of the response to natriuretic peptides or among post-myocardial infarction patients in the absence of HF when there may not be a need for increased natriuretic peptide availability. Furthermore, there is a need for additional studies to determine the long-term effects of ARNi on albuminuria, obesity, glycemic control and lipid profile, blood pressure, and cognitive function in patients with HF.
The effects of angiotensin receptor-neprilysin inhibitors on clinical outcomes in heart failure with mildly reduced or preserved ejection fraction: real-world evidence from the CCA Database-HF Center

Z Xie,X Cui,Y Xu,Y Wang,Y Dong,Y Liao,W Li,X Li,J Yang,J Zhou,J Ge

DOI: https://doi.org/10.1093/eurheartj/ehae666.1089

IF: 39.3

2024-10-30

European Heart Journal

Abstract:Background Recent clinical trials have demonstrated the potential efficacy and safety of angiotensin receptor-neprilysin inhibitors (ARNI) in patients with heart failure (HF) with mildly reduced or preserved ejection fraction. Nevertheless, the generalizability of these findings in real-world clinical settings remains to be determined. We aimed to compare the real-world effectiveness of ARNI versus angiotensin-converting enzyme inhibitor/angiotensin receptor blocker (ACEI/ARB)on clinical outcomes in HF patients with mildly reduced or preserved ejection fraction. Methods Patient-level data was derived from the China Cardiovascular Association Database-HF Center Registry. We included exclusively a subpopulation of HF patients with left ventricular ejection fraction (LVEF) >40% and comorbid with hypertension. Patients prescripted with ARNI at discharge and sustaining to ARNI therapy during follow-up were categorized as the ARNI group, while those maintaining the usage of ACEI/ARB after discharge were designated as the ACEI/ARB group. In complete cases, the primary endpoint of all-cause mortality at one year was assessed by the 1:1 propensity score matching (PSM) method. Results In all HF patients with LVEF >40% comorbid with hypertension, the usage of ARNI has increased from 0.9% in 2017 to 37.2% in 2021. A total of 3348 patients in the ARNI group and 7688 patients in the ACEI/ARB group were identified for comparative effectiveness. After 1:1 PSM, 5482 patients were included in the primary analysis, with 2741 patients in each treatment arm. The proportion of patients receiving higher dosages of ARNI (200mg/d and 400mg/d) was 20.9%, 26.6%, 29.2%, and 30.3% at discharge, 1-month, 3-month, and 1-year, respectively. Over the 1-year follow-up, ARNI was associated with a 20% relative reduction in all-cause death compared to the ACEI/ARB therapy (10.5% vs. 12.9%, adjusted hazard ratio [HR], 0.80 [95% CI, 0.69-0.94], P=0.005). The absolute risk difference in all-cause death between ARNI and ACEI/ARB arms was 2.88 per 100 patient-years (incidence rate difference, -2.88 [95% CI, -4.86 to -0.9]). Cardiovascular death also tended to decrease in the ARNI group but with missed statistical significance (4.5% vs. 4.9%, adjusted HR, 0.89 [95% CI, 0.70-1.14], P=0.373). Treatment benefits were more significant in those with LVEF between 40-50% (adjusted HR, 0.62 [95% CI, 0.48-0.79]), 50-60% (adjusted HR, 0.85 [95% CI, 0.68-1.06]), but not observed in HF patients with LVEF>60% (adjusted HR, 1.80 [95% CI, 1.08-2.98]; Pinteraction<0.001). Conclusion In real-world clinical settings, treatment with ARNI was associated with a significant relative risk reduction in all-cause mortality compared with ACEI/ARB in HF patients with mildly reduced or preserved LVEF. The cardiovascular benefit was concentrated in patients with LVEF ≤60%.

cardiac & cardiovascular systems

An improved ion-exchange procedure for the chromatography of the metabolites of mevalonate.

Indian Consensus on the Role and Position of Angiotensin Receptor-neprilysin Inhibitors in the Management of Heart Failure

Evidence-based Consensus On The Use Of Sacubitril Valsartan For Heart Failure Management In India

Consensus Statement from India on the Renal Benefits of ARNi, SGLT-2i, and Bisoprolol in Chronic Kidney Disease

State of the art on angiotensin-neprilysin inhibitors

Practical approach to vasculitis.

Angiotensin receptor-neprilysin inhibitor in patients with heart failure and chronic kidney disease

Effects of sacubitril-valsartan on heart failure patients with mid-range ejection fractions: A systematic review and meta-analysis

Impact of angiotensin receptor-neprilysin inhibition (ARNI) in improving ejection fraction and left and right ventricular remodeling in heart failure

Angiotensin Receptor–Neprilysin Inhibitor in Heart Failure Patients With Renal Dysfunction

Efficacy of Sacubitril-Valsartan on Survival and Cardiac Remodeling in Hypotensive Heart Failure With Reduced Ejection Fraction: A Multicenter Study

The Difference between Sacubitril Valsartan and Valsartan on Vascular Endothelial Function, APN, MMP-9, and BNP Levels in Patients with Hypertension and Chronic Heart Failure

Real-world experience of angiotensin receptor-neprilysin inhibitors in patients with heart failure and dialysis

Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction: Rationale and Design of the PARAGON-HF Trial.

Use and Benefit of Sacubitril/Valsartan in Elderly Patients with Heart Failure with Reduced Ejection Fraction

Sacubitril/valsartan and arrhythmic burden in patients with heart failure and reduced ejection fraction: a systematic review and meta-analysis

Angiotensinogen and Natriuretic Peptide mRNAs in Rat Brain: Localization and Differential Regulation by Adrenal Steroids in Hypothalamus

Angiotensin Receptor-Neprilysin Inhibitors in Patients With Heart Failure With Reduced Ejection Fraction and Advanced Chronic Kidney Disease: A Retrospective Multi-Institutional Study

Safety and efficacy of angiotensin receptor neprilysin inhibitor in improving cardiac function and blood pressure in dialysis patients

Neprilysin Inhibitors in Heart Failure: The Science, Mechanism of Action, Clinical Studies, and Unanswered Questions

The effects of angiotensin receptor-neprilysin inhibitors on clinical outcomes in heart failure with mildly reduced or preserved ejection fraction: real-world evidence from the CCA Database-HF Center